Some alternative medicine practitioners believe that IgG antibodies contribute to food sensitivities
However, evidence shows that weight loss improves fibromyalgia pain severity in obese patients, and GLP-1 therapy produces sustained weight loss (15-22% over 68 weeks in trials) while improving insulin sensitivity and reducing inflammatory markersfactors that may support fibromyalgia management indirectly
10.1007/s13555-018-0278-6 2 AlonsoL.FuchsE
Reducing the most harmful drinking patterns could make a meaningful difference for patients. In a linked commentary, also published in The Lancet, academics from the US said: The importance of evaluating GLP-1 therapies as new therapeutic options for alcohol use disorder cannot be overstated, Should forthcoming studies confirm efficacy of GLP-1 therapies for alcohol use disorder across a broad range of populations and settings, public health implications could be substantial a possibility that deserves celebration. Commenting on the study, Dr Marie Spreckley, research programme manager at the University of Cambridge, said: Overall, this study provides encouraging early evidence for a potential new treatment approach for people with co-occurring obesity and alcohol use disorder, but larger and longer-term trials in more diverse populations are needed before this can inform routine clinical practice. Matt Field, professor of psychology at the University of Sheffield, said: This well-conducted trial showed that 26 weeks of semaglutide treatment led to a marked reduction in the frequency of heavy drinking among people with alcohol use disorder who were also obese
[DOI] [PMC free article] [PubMed] [Google Scholar] 86.Zhou Y, Wang S, Luo H, et al
The MHRA has raided two UK manufacturing sites producing counterfeit retatrutide and tirzepatide in the last seven months
